Neutral
●
PRNewsWire
●
5 months ago
New changes expected to deliver significant client savings while maintaining rigorous clinical standards WOONSOCKET, R.I., May 5, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced updates to its most common commercial template formularies that will expand the use of lower-cost biosimilars across multiple therapeutic categories, including changes effective July 1, 2026, that will prefe...